| NASDAQ: ANTH|
| Paul F. Truex
(President and CEO)|
ANTH (NASDAQ) US$ 0.69 0.00 (+0.58%)24 Feb, 4:00 PM GMT-5 - Disclaimer
Hayward, California, United States
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. A-623 (Blisibimod) is Anthera’s leading drug candidate which is being developed for treatment of both systemic lupus erythematosus and IgA nephropathy.
Blisibimod is a selective peptibody antagonist of B-cell activating factor (BAFF). BAFF is critical to the development, maintenance and survival of B-cells, but is known to be up-regulated in autoimmune diseases. It is primarily expressed by macrophages, monocytes and dendritic cells. Blisibimod binds to BAFF and inhibits the interaction of BAFF with its receptors. Blisibimod is currently being evaluated in clinical trials in lupus  and  and IgA nephropathy .
Anthera Pharmaceuticals Wikipedia
July 2014, Anthera acquired Sollpura (Liprotamase) from Eli Lilly and Company. Sollpura is an investigational pancreatic enzyme replacement therapy (PERT) that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.